Hidden protein drives drug resistance in aggressive breast cancer

Researchers identified a estrogen receptor variant that enables triple-negative breast cancer cells to survive chemotherapy and regenerate tumors. The finding could reshape treatment strategies for a cancer type that currently lacks targeted therapies, opening paths toward combination drugs that disable both the tumor and its resistance mechanism.

Originaltitel: Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer